Howard G. Welgus net worth and biography

Howard Welgus Biography and Net Worth

Dr. Welgus was Chief Medical Officer of Arcutis from 2016 to July 2020, when he retired and was appointed to the Board of Directors. He is a board-certified dermatologist who received his medical and scientific training at Washington University School of Medicine in St. Louis. After completing a residency in Dermatology, he stayed on faculty at Washington University for 17 years, becoming a tenured full Professor and publishing over 120 articles.

Dr. Welgus joined Pfizer in 1999, where he spent 10 years as VP and head of the Dermatology and Inflammation therapeutic areas at the Ann Arbor site. During this time, he was involved in developing Lyrica® for fibromyalgia and Xeljanz® for rheumatoid arthritis and psoriasis. He then spent 3 years at Nycomed as Chief Medical Officer and head of R&D, and then was Chief Medical Officer at Verrica Pharmaceuticals.

Dr. Welgus is a Fellow of the American Academy of Dermatology and is a member of several prestigious medical societies including the American Dermatologic Association, the American Society of Clinical Investigation, and the Association of American Professors. He received his B.A. in Biology from Rice University.

What is Howard G. Welgus' net worth?: The estimated net worth of Howard G. Welgus is at least $2.41 million as of December 2nd, 2024. Dr. Welgus owns 161,944 shares of Arcutis Biotherapeutics stock worth more than $2,406,488 as of December 18th. This net worth estimate does not reflect any other investments that Dr. Welgus may own. Learn More about Howard G. Welgus' net worth.
How do I contact Howard G. Welgus?: The corporate mailing address for Dr. Welgus and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Howard G. Welgus' contact information.
Has Howard G. Welgus been buying or selling shares of Arcutis Biotherapeutics?: During the past quarter, Howard G. Welgus has sold $304,200.00 in shares of Arcutis Biotherapeutics stock. Most recently, Howard G. Welgus sold 10,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.51, for a transaction totalling $125,100.00. Following the completion of the sale, the director now directly owns 161,944 shares of the company's stock, valued at $2,025,919.44. Learn More on Howard G. Welgus' trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 1,093 shares worth more than $7,771.23. During the last year, insiders at the sold shares 20 times. They sold a total of 151,399 shares worth more than $1,463,405.27. The most recent insider tranaction occured on December, 2nd when Director Howard G Welgus sold 10,000 shares worth more than $125,100.00. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 12/2/2024.

Howard G. Welgus Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2024	Sell	10,000	$12.51	$125,100.00	161,944
11/1/2024	Sell	10,000	$8.65	$86,500.00	171,944
10/1/2024	Sell	10,000	$9.26	$92,600.00	181,944
9/3/2024	Sell	10,000	$10.77	$107,700.00	191,944
8/1/2024	Sell	10,000	$9.87	$98,700.00	176,953
7/1/2024	Sell	10,000	$9.31	$93,100.00	180,339
4/17/2023	Sell	8,500	$13.97	$118,745.00	165,825
4/6/2023	Sell	8,500	$12.01	$102,085.00	165,825
2/15/2023	Sell	8,500	$16.98	$144,330.00	165,825
1/17/2023	Sell	8,500	$13.72	$116,620.00	165,825
10/4/2022	Sell	6,000	$20.29	$121,740.00	168,208
8/15/2022	Sell	6,000	$24.80	$148,800.00	174,208
7/18/2022	Sell	6,000	$24.40	$146,400.00	180,208
6/1/2022	Sell	2,500	$20.62	$51,550.00	181,896
5/2/2022	Sell	2,500	$20.44	$51,100.00	181,896
4/1/2022	Sell	7,500	$20.02	$150,150.00
1/3/2022	Sell	2,500	$21.21	$53,025.00
12/23/2021	Sell	2,500	$20.16	$50,400.00
11/1/2021	Sell	2,500	$21.81	$54,525.00
7/1/2021	Sell	2,200	$26.13	$57,486.00
4/1/2021	Sell	2,200	$29.49	$64,878.00
12/1/2020	Sell	2,200	$25.98	$57,156.00	180,234
10/1/2020	Sell	2,200	$27.65	$60,830.00	179,210
9/1/2020	Sell	2,200	$24.38	$53,636.00	178,378
8/3/2020	Sell	2,800	$25.63	$71,764.00	162,725

Howard G. Welgus Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $14.29

$14.14

$14.99

50 Day Range

MA: $10.37

$8.31

$13.57

2 Week Range

Now: $14.29

$2.28

$15.02

Volume

477,479 shs

Average Volume

3,122,827 shs

Market Capitalization

$1.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.